Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction
- PMID: 38639358
- PMCID: PMC11179922
- DOI: 10.1161/JAHA.123.033410
Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction
Abstract
Background: Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value of urinary proteomics. The objective of our study was to identify urinary proteins/peptides associated with death and heart failure admission in patients with heart failure with preserved ejection fraction.
Methods and results: The study population included participants enrolled in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial). The relationship between urine protein levels and the risk of death or heart failure admission was assessed using Cox regression, in both nonadjusted analyses and adjusting for urine creatinine levels, and the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score. A total of 426 (12.4%) TOPCAT participants had urinary protein data and were included. There were 40 urinary proteins/peptides significantly associated with death or heart failure admission in nonadjusted analyses, 21 of which were also significant adjusted analyses. Top proteins in the adjusted analysis included ANGPTL2 (angiopoietin-like protein 2) (hazard ratio [HR], 0.5731 [95% CI, 0.47-0.7]; P=3.13E-05), AMY2A (α amylase 2A) (HR, 0.5496 [95% CI, 0.44-0.69]; P=0.0001), and DNASE1 (deoxyribonuclease-1) (HR, 0.5704 [95% CI, 0.46-0.71]; P=0.0002). Higher urinary levels of proteins involved in fibrosis (collagen VI α-1, collagen XV α-1), metabolism (pancreatic α-amylase 2A/B, mannosidase α class 1A member 1), and inflammation (heat shock protein family D member 1, inducible T cell costimulatory ligand) were associated with a lower risk of death or heart failure admission.
Conclusions: Our study identifies several novel associations between urinary proteins/peptides and outcomes in heart failure with preserved ejection fraction. Many of these associations are independent of clinical risk scores and may aid in risk stratification in this patient population.
Keywords: biomarkers; heart failure with preserved ejection fraction; prognosis; proteomics; urine proteomics.
Figures
Similar articles
-
Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc. 2024 Sep 3;13(17):e033660. doi: 10.1161/JAHA.123.033660. Epub 2024 Aug 29. J Am Heart Assoc. 2024. PMID: 39206761
-
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.Circ Heart Fail. 2014 Sep;7(5):740-51. doi: 10.1161/CIRCHEARTFAILURE.114.001583. Epub 2014 Aug 13. Circ Heart Fail. 2014. PMID: 25122186 Free PMC article. Clinical Trial.
-
Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.J Am Heart Assoc. 2018 Feb 23;7(5):e007475. doi: 10.1161/JAHA.117.007475. J Am Heart Assoc. 2018. PMID: 29475874 Free PMC article. Clinical Trial.
-
Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.Minerva Cardioangiol. 2017 Aug;65(4):427-442. doi: 10.23736/S0026-4725.16.04293-6. Epub 2016 Dec 13. Minerva Cardioangiol. 2017. Retraction in: Minerva Cardiol Angiol. 2023 Oct;71(5):608. doi: 10.23736/S2724-5683.23.06418-9. PMID: 27958695 Retracted. Review.
-
Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.Curr Heart Fail Rep. 2017 Aug;14(4):217-222. doi: 10.1007/s11897-017-0336-x. Curr Heart Fail Rep. 2017. PMID: 28647918 Review.
References
-
- Hanff TC, Cohen JB, Zhao L, Javaheri A, Zamani P, Prenner SB, Rietzschel E, Jia Y, Walsh A, Maranville J, et al. Quantitative proteomic analysis of diabetes mellitus in heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2021;6:89–99. doi: 10.1016/j.jacbts.2020.11.011 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
